
Teva re-elects Chairman of the Board
pharmafile | May 18, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Frost, Teva
Teva has announced that its Board of Directors has unanimously voted to re-elect Dr Phillip Frost as Chairman of the Board for a term of three years.
Frost’s re-election as a director is subject to shareholder approval at an upcoming annual meeting of shareholders.
Commenting on the Board’s decision, Professor Moshe Many, vice chairman of the Board, stated: “Dr Phillip Frost has the Board’s full support. We would continue to benefit from his vision and guidance.
“We look forward to the progress of the Company under the governance of the Board and the leadership of Teva’s president and chief executive Dr Jeremy Levin.”
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …





